Efficacy and safety of micafungin, an echinocandin antifungal agent, on invasive fungal infections in patients with hematological disorders

Leukemia and Lymphoma

Volumn 50, Issue 1, 2009, Pages 92-100

  Tamura, Kazuo ^a   Urabe, Akio ^b   Yoshida, Minoru ^c   Kanamaru, Akihisa ^d   Kodera, Yoshihisa ^e   Okamoto, Shinichiro ^f   Maesaki, Shigefumi ^g   Masaoka, Tohru ^h  

^a FUKUOKA UNIVERSITY   (Japan)

^b Kanto Medical Center   (Japan)

^c TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e JAPANESE RED CROSS NAGOYA FIRST HOSPITAL   (Japan)

^f KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g SAITAMA MEDICAL UNIVERSITY HOSPITAL   (Japan)

^h OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

Author keywords

Echinocandin; Empirical therapy; Febrile neutropenia; Fungal infection; Hematological disorders; Micafungin

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMINOTRANSFERASE; AMPHOTERICIN B; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; ECHINOCANDIN; FLUCONAZOLE; GAMMA GLUTAMYLTRANSFERASE; ITRACONAZOLE; LACTATE DEHYDROGENASE; MICAFUNGIN; NITROGEN; POTASSIUM; SODIUM; UREA;

ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANDIDIASIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ELECTROLYTE DISTURBANCE; FEBRILE NEUTROPENIA; FEMALE; FUNGUS CULTURE; HEMATOLOGIC DISEASE; HEMATOLOGIC MALIGNANCY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LABORATORY TEST; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYCOSIS; NEPHROTOXICITY; OUTCOME ASSESSMENT; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIODIAGNOSIS; SIDE EFFECT; SINGLE DRUG DOSE; SODIUM BLOOD LEVEL; TREATMENT DURATION; UREA NITROGEN BLOOD LEVEL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; ANTIFUNGAL AGENTS; ECHINOCANDINS; FEMALE; HEMATOLOGIC DISEASES; HUMANS; LEUKOCYTE COUNT; LIPOPEPTIDES; MALE; MIDDLE AGED; MYCOSES; NEUTROPHILS;

EID: 59249099656     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190802635500     Document Type: Article

References (29)

1. Vartivarian, S. E., Anaissie, E. J. and Bodey, G. P. (1993) Emerging fungal pathogens in immunocompromised patients: Classification, diagnosis, and management. Clin Infect Dis, 17, pp. S487-S491.
2. Kume, H., Yamazaki, T., Abe, M., Tanuma, H., Okudaira, M. and Okayasu, I. (2006) Epidemiology of visceral mycoses in patients with leukemia and MDS - Analysis of the data in annual of pathological autopsy cases in Japan in 1989, 1993, 1997 and 2001. Jpn J Med Mycol, 47, pp. 15-24.
3. Hatano, K., Morishita, Y., Nakai, T. and Ikeda, F. (2002) Antifungal mechanism of FK463 against Candida albicans and Aspergillus fumigatus. J Antibiot (Tokyo), 55, pp. 219-222.
4. Tawara, S., Ikeda, F., Maki, K., Morishita, Y., Otomo, K. Teratani, N. et al. (2000) In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob Agents Chemother, 44, pp. 57-62.
5. Ostrosky-Zeichner, L., Rex, J. H., Pappas, P. G., Hamill, R. J., Larsen, R. A. Horowitz, H. W. et al. (2003) Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother, 47, pp. 3149-3154.
6. Kohno, S., Masaoka, T., Yamaguchi, H., Mori, T., Urabe, A. Ito, A. et al. (2004) A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan. Scand J Infect Dis, 36, pp. 372-379.
7. Ostrosky-Zeichner, L., Kontoyiannis, D., Raffalli, J., Mullane, K. M., Vazquez, J. Anaissie, E. J. et al. (2005) International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. Eur J Clin Microbiol Infect Dis, 24, pp. 654-661.
8. Denning, D. W., Marr, K. A., Lau, W. M., Facklam, D. P., Ratanatharathorn, V. Becker, C. et al. (2006) Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect, 53, pp. 337-349.
9. de Wet, N TE, Bester, A. J., Viljoen, J. J., Filho, F., Suleiman, J. M. Ticona, E. et al. (2005) A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis. Aliment Pharmacol Ther, 21, pp. 899-907.
10. Kuse, E-R, Chetchotisakd, P., da Cunha, C. A., Ruhnke, M., Barrios, C., Raghunadharao, D. Micafungin Invasive Candidiasis Working Group et al. (2007) Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: A phase III randomised double-blind trial. Lancet, 369, pp. 1519-1527.
11. Pappas, P. G., Rotstein, C MF, Betts, R. F., Nucci, M., Talwar, D. De Waele, J. J. et al. (2007) Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis, 45, pp. 883-893.
12. Ishikawa, T., Takata, T., Tomoyose, T., Masuda, M., Nakachi, S. Koga, S. et al. (2006) The efficacy of micafungin as an empiric therapy for febrile neutropenic patients refractory to antibacterial agents. Jpn J Chemother, 54, pp. 125-128.
13. Yanada, M., Kiyoi, H., Murata, M., Suzuki, M., Iwai, M. Yokozawa, T. et al. (2006) Micafungin, a novel antifungal agent, as empirical therapy in acute leukemia patients with febrile neutropenia. Intern Med, 45, pp. 259-264.
14. Toubai, T., Tanaka, J., Ota, S., Shigematsu, A., Shono, Y. Ibata, M. et al. (2007) Efficacy and safety of micafungin in febrile neutropenic patients treated for hematological malignancies. Intern Med, 46, pp. 3-9.
15. Hashino, S., Morita, L., Takahata, M., Onozawa, M., Nakagawa, M. Kawamura, T. et al. (2008) Administration of micafungin as prophylactic antifungal therapy in patients undergoing allogeneic stem cell transplantation. Int J Hematol, 87, pp. 91-97.
16. van Burik, J AH, Ratanatharathorn, V., Stepan, D. E., Miller, C. B., Lipton, J. H., Vesole, D. H. National Institute of Allergy and Infectious Diseases Mycoses Study Group et al. (2004) Micafungin versus fluconazlole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis, 39, pp. 1407-1416.
17. de Pauw, B., Walsh, T. J., Donnelly, J. P., Stevens, D. A., Edwards, J. E. Calandra, T. et al. (2008) Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/ MSG) Consensus Group. Clin Infect Dis, 46, pp. 1813-1821.
18. (2007) Guidelines for Mangement of Deep-seated Mycoses, Kyowa Kikaku Ltd., Tokyo
19. Herbrecht, R., Denning, D. W., Patterson, T. F., Bennett, J. E., Greene, R. E. Oestmann, J. W. et al. (2002) Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med, 347, pp. 408-415.
20. Karthaus, M. (2002) Voriconazole versus amphotericin B for invasive aspergillosis. N Engl J Med, 347, pp. 2080-2081.
21. Ullmann, A. J. (2003) Review of the safety, tolerability, and drug interactions of the new antifungal agents caspofungin and voriconazole. Curr Med Res Opin, 19, pp. 263-271.
22. Ikeda, F., Tanaka, S., Ohki, H., Matsumoto, S., Maki, K. Katashima, M. et al. (2007) Role of micafungin in the antifungal armamentarium. Curr Med Chem, 14, pp. 1263-1275.
23. Shimizu, T., Ochiai, H., Asell, F., Shimizu, H., Saitoh, R. Hama, Y. et al. (2003) Bioinformatics research on inter-racial difference in drug metabolism. I. Analysis on frequencies of mutant alleles and poor metabolizers on CYP2D6 and CYP2C19. Drug Metab Pharmacokinet, 18, pp. 48-70.
24. Wingard, J. R. (2004) Empirical antifungal therapy in treating febrile neutropenic patients. Clin Infect Dis, 39, pp. S38-S43.
25. Walsh, T. J., Finberg, R. W., Arndt, C., Hiemenz, J., Schwartz, C., Bodensteiner, D. National Institute of Allergy and Infectious Diseases Mycoses Study Group et al. (1999) Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med, 340, pp. 764-771.
26. Boogaerts, M., Winston, D. J., Bow, E. J., Garber, G., Reboli, A. C., Schwarer, A. P. Itraconazole Neutropenia Study Group et al. (2001) Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. Ann Intern Med, 135, pp. 412-422.
27. Walsh, T. J., Pappas, P., Winston, D. J., Lazarus, H. M., Petersen, F., Raffalli, J. National Institute of Allergy and Infectious Diseases Mycoses Study Group et al. (2002) Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med, 346, pp. 225-234.
28. Walsh, T. J., Teppler, H., Donowitz, G. R., Maertens, J. A., Baden, L. R. Dmoszynska, A. et al. (2004) Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med, 351, pp. 1391-1402.
29. Marr, K. A., Boeckh, M., Carter, R. A., Kim, H. W. and Corey, L. (2004) Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis, 39, pp. 797-802.